Trending Now
Sarepta Therapeutics Inc. (NASDAQ:SRPT) Releases Update On SRP-9001 Gene Therapy Program...
Sarepta Therapeutics Inc. (NASDAQ:SRPT) has announced the completion of a Type C 'written response only' meeting with the FDA's Centre for Biologics Evaluation and...
DIH Holding US, Inc. (DHAI): Pioneering Rehabilitation with Cutting-Edge Technology
Let’s talk about something truly inspiring: the future of rehabilitation. On December 23, 2024, DIH Holding US, Inc. (NASDAQ: DHAI) announced...
Predictive Oncology Inc. (Nasdaq: POAI): A Transformative Acquisition by Renovaro Inc.
The biotechnological domain is currently abuzz with developments surrounding the acquisition of Predictive Oncology Inc. (Nasdaq: POAI) by Renovaro Inc. (Nasdaq: RENB)....
Popular News
GeneDx Holdings Corp. (WGS) Bolsters Financial and Strategic Position in 2024
GeneDx Holdings Corp. (NASDAQ: WGS), a prominent player in genomic insights and improved health outcomes, has made significant strides in the first...
MAKE IT MODERN
LATEST REVIEWS
Geneos Therapeutics Inc, a subsidiary of Inovio Pharmaceuticals Inc (NASDAQ: INO),...
Geneos Therapeutics, a subsidiary of Inovio Pharmaceuticals Inc (NASDAQ: INO), has received a Series A2 financing of $17 million. Flerie Invest was in charge...
MAKE IT MODERN
PERFORMANCE TRAINING
Why Temas Resources Corp. Could Become the Biggest Commodities Breakout of 2022 (GOLD, BHP,...
The USA economy is trying hard to come back to the pre-pandemic normalcy. January has seen lots of up and down but...
Pfizer Inc. (NYSE:PFE) And Sangamo Therapeutics Inc. (NASDAQ:SGMO) Reports Giroctocogene Fitelparvovec Study Data
Pfizer Inc. (NYSE:PFE) and Sangamo Therapeutics Inc. (NASDAQ:SGMO) have announced updated follow-up data from their Phase 1/2 giroctocogene fitelparvovec (PF-07055480 or SB-525)...
FATE, ATRX, and GBT in Focus as Cancer Small Caps Trend Higher (DVAX, BMY,...
One key metric that allows us to see under the surface of the market is “relative strength”, or how well a stock is faring...
Immunomedics, Inc. (NASDAQ:IMMU) Expands Its Current Clinical Collaboration with Roche to Evaluate Trodelvy
Today, many companies are stepping out of their personalized healthcare strategy to accommodate collaborations. This way, they can advance their research and development efforts....
AbCellera (NASDAQ: ABCL) Receives EUA Expansion For Bamlanivimab and Etetsevimab in SARS-CoV-2 Treatment In...
AbCellera (NASDAQ: ABCL) has announced FDA expansion of the EUA for bamlanivimab (LY-CoV55) 700 mg given with etesevimab 1400 mg to include post-exposure prophylaxis...
MAKE IT MODERN
